US Bancorp’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

US Bancorp’s Portfolio AVEO Stock Details AVEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-102	Closed	-$1.52K	–	4269
2022 Q4	$1.52K	Buy	+102	New	+$1.41K	﹤0.01%	3847
2019 Q4	–	Sell	-400	Closed	-$3K	–	3786
2019 Q3	$3K	Hold	400	–	–	﹤0.01%	3384
2019 Q2	$3K	Buy	+400	New	+$3.43K	﹤0.01%	3419
2019 Q1	–	Sell	-200	Closed	-$3K	–	3712
2018 Q4	$3K	Hold	200	–	–	﹤0.01%	3375
2018 Q3	$7K	Buy	+200	New	+$5.14K	﹤0.01%	3247
2018 Q2	–	Sell	-100	Closed	-$3K	–	3745
2018 Q1	$3K	Buy	+100	New	+$2.93K	﹤0.01%	3454
2016 Q3	–	Sell	-50	Closed	–	–	3672
2016 Q2	$0	Buy	+50	New	+$482	﹤0.01%	3692

US Bancorp's AVEO Position: Q1 2023 in Review

US Bancorp sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2023, closing a stake of 102 shares — an estimated $1.52K sold.

US Bancorp first reported a position in AVEO in Q2 2016 and held it in 7 quarters. The position peaked at $7K in Q3 2018. 0 funds tracked by Wall St. Rank hold AVEO as of Q1 2023.

US Bancorp reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
US Bancorp sold 102 AVEO Pharmaceuticals, Inc. shares in Q1 2023, an estimated $1.52K.
US Bancorp first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2016 and held it in 7 quarters.
US Bancorp's AVEO Pharmaceuticals, Inc. position peaked at $7K in Q3 2018.
0 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2023.

Based on US Bancorp's 13F filing for Q1 2023, filed 9 May 2023.